Application of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after PCI for acute myocardial infarction
Objective To investigate the application value of Sacubitril/Valsartan sodium tablets combined with Tongxinluo capsules in patients after percutaneous coronary intervention(PCI)for acute myocardial infarction(AMI).Methods A total of 194 AMI patients who underwent PCI at Xi'an Hospital of Traditional Chinese Medicine from November 2021 to October 2023 were selected for the study objects.They were randomly divided into a control group(97 cases)and a combined group(97 cases)using computer coding method.In the control group,there were 56 males and 41 females,aged 36-74(55.83±8.42)years,1-6(3.49±0.63)h after PCI.There were 53 males and 44 females in the combined group,aged 36-75(55.87±8.46)years,1-6(3.53±0.58)h after PCI.The control group was treated with Sacubitril/Valsartan sodium tablets combined with conventional treatment,while the combined group additionally received Tongxinluo capsules.After 8 weeks of treatment,they were followed up for 6 months.The blood flow grading of thrombolysis in myocardial infarction(TIMI),cardiac function[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF)]and levels of inflammatory factors[hypersensitive C-reactive protein(hs-CRP)and interleukin(IL)-6]before and after treatment,and incidence of major adverse cardiovascular events(MACE)during follow-up were compared between the two groups.Independent sample t test,paired t test,rank sum test,andx2test were used.Results After treatment,the TIMI blood flow grading in the combined group was better than that in the control group(P＜0.05).After treatment,the LVESD[(32.44±4.29)mm]and LVEDD[(40.35±4.92)mm]in the combined group were lower than those in the control group[(38.64±4.82)mm and(47.82±5.73)mm],and the LVEF[(65.83±5.78)％]was higher than that in the control group[(58.36±5.36)％](all P＜0.05);the levels of hs-CRP[(3.11±1.28)mg/L]and IL-6[(12.43±3.27)ng/L]in the combined group were lower than those in the control group[(6.84±1.93)mg/L and(15.68±3.94)ng/L](both P＜0.05).During follow-up,the total incidence of MACE in the combined group[12.37％(12/97)]was lower than that in the control group[26.80％(26/97)](P＜0.05).Conclusion The combination of Sacubitril/Valsartan sodium tablets and Tongxinluo capsules can improve the cardiac function and the levels of inflammatory factors in AMI patients after PCI,and reduce the total incidence of MACE.
万方数据
维普
